Wayne Rackoff

3.9k total citations · 2 hit papers
35 papers, 2.9k citations indexed

About

Wayne Rackoff is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Wayne Rackoff has authored 35 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 11 papers in Genetics and 11 papers in Oncology. Recurrent topics in Wayne Rackoff's work include Hemoglobinopathies and Related Disorders (8 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Neutropenia and Cancer Infections (5 papers). Wayne Rackoff is often cited by papers focused on Hemoglobinopathies and Related Disorders (8 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Neutropenia and Cancer Infections (5 papers). Wayne Rackoff collaborates with scholars based in United States, France and United Kingdom. Wayne Rackoff's co-authors include Steven Sun, Margaret Tonda, Alan N. Gordon, Hiroji Uemura, Fred Saad, Angela Lopez‐Gitlitz, David Olmos, Boris Hadaschik, Margaret K. Yu and Ji Youl Lee and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Wayne Rackoff

35 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

2018 868 citations Matthew R. Smith, Fred Saad et al. New England Journal of Medicine profile →
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

2007 505 citations Wayne Rackoff et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wayne Rackoff United States	19	1.0k	945	823	766	362	35	2.9k
Gerardo Colón‐Otero United States	30	2.0k 2.0×	608 0.6×	407 0.5×	595 0.8×	528 1.5×	99	3.5k
N. Tubiana-Mathieu France	30	2.0k 1.9×	644 0.7×	268 0.3×	436 0.6×	630 1.7×	166	3.2k
F. Cavalli Switzerland	33	2.2k 2.1×	660 0.7×	369 0.4×	705 0.9×	652 1.8×	147	4.0k
Teresa Gamucci Italy	28	2.3k 2.3×	688 0.7×	264 0.3×	827 1.1×	723 2.0×	128	3.5k
George D. Demetri United States	32	1.8k 1.8×	2.0k 2.1×	890 1.1×	1.3k 1.7×	380 1.0×	104	5.0k
Guy C. Toner Australia	32	1.4k 1.3×	1.2k 1.2×	316 0.4×	609 0.8×	268 0.7×	124	3.6k
Ralph M. Meyer Canada	36	1.7k 1.7×	827 0.9×	1.5k 1.8×	449 0.6×	193 0.5×	139	4.7k
Ralph Levitt United States	27	2.1k 2.1×	892 0.9×	348 0.4×	670 0.9×	273 0.8×	67	3.6k
Steve Dahlberg United States	22	1.4k 1.4×	460 0.5×	647 0.8×	747 1.0×	177 0.5×	40	3.4k
W M Hryniuk Canada	22	1.9k 1.8×	570 0.6×	377 0.5×	386 0.5×	678 1.9×	32	3.2k

Countries citing papers authored by Wayne Rackoff

Since Specialization

Citations

This map shows the geographic impact of Wayne Rackoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wayne Rackoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wayne Rackoff more than expected).

Fields of papers citing papers by Wayne Rackoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wayne Rackoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wayne Rackoff. The network helps show where Wayne Rackoff may publish in the future.

Co-authorship network of co-authors of Wayne Rackoff

This figure shows the co-authorship network connecting the top 25 collaborators of Wayne Rackoff. A scholar is included among the top collaborators of Wayne Rackoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wayne Rackoff. Wayne Rackoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Small, Eric J., Fred Saad, Simon Chowdhury, et al.. (2019). Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology. 37(7_suppl). 144–144. 8 indexed citations

Smith, Matthew R., Fred Saad, Simon Chowdhury, et al.. (2018). Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. New England Journal of Medicine. 378(15). 1408–1418. 868 indexed citations breakdown →

Twyman, Kathryn, et al.. (2015). A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds. Clinical Pharmacology & Therapeutics. 98(5). 506–513. 29 indexed citations

Raponi, Mitch, Jean‐Luc Harousseau, Jeffrey E. Lancet, et al.. (2007). Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia. Clinical Cancer Research. 13(7). 2254–2260. 52 indexed citations

Harousseau, Jean‐Luc, Jeffrey E. Lancet, Josy Reiffers, et al.. (2007). A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 109(12). 5151–5156. 59 indexed citations

Gordon, Alan N., Margaret Tonda, Steven Sun, & Wayne Rackoff. (2004). Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecologic Oncology. 95(1). 1–8. 337 indexed citations

Cortes, Jörge E., Guillermo Garcia‐Manero, Susan O’Brien, et al.. (2004). A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.. Blood. 104(11). 1011–1011. 15 indexed citations

Dean, Deborah, Lynne Neumayr, Samir K. Ballas, et al.. (2003). Chlamydia pneumoniae and Acute Chest Syndrome in Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology. 25(1). 46–55. 38 indexed citations

Rackoff, Wayne, Q. J. Ge, Harland N. Sather, et al.. (1999). Central Venous Catheter Use and the Risk of Infection in Children With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 21(4). 260–267. 28 indexed citations

10.

Uchida, Kou, et al.. (1998). Effect of erythrocytapheresis on arterial oxygen saturation and hemoglobin oxygen affinity in patients with sickle cell disease. American Journal of Hematology. 59(1). 5–8. 23 indexed citations

11.

Uchida, Kou, Wayne Rackoff, Kwaku Ohene‐Frempong, et al.. (1998). Effect of erythrocytapheresis on arterial oxygen saturation and hemoglobin oxygen affinity in patients with sickle cell disease. American Journal of Hematology. 59(1). 5–8. 1 indexed citations

12.

Rackoff, Wayne, et al.. (1996). Predicting the risk of bacteremia in childen with fever and neutropenia.. Journal of Clinical Oncology. 14(3). 919–924. 178 indexed citations

13.

Rackoff, Wayne, et al.. (1995). A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children. The Journal of Pediatrics. 127(1). 147–151. 80 indexed citations

14.

Rackoff, Wayne, et al.. (1994). Utilization of a pediatric emergency department by patients with sickle cell disease. Pediatric Emergency Care. 10(2). 79–82. 8 indexed citations

15.

Rackoff, Wayne, et al.. (1994). A case-control retrospective study of the efficacy of granulocyte-colony-stimulating factor in children with neuroblastoma.. PubMed. 16(2). 132–7. 9 indexed citations

16.

Rackoff, Wayne & Catherine S. Manno. (1994). Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone.. PubMed. 16(2). 156–9. 18 indexed citations

17.

Rackoff, Wayne, et al.. (1992). Neurologic events after partial exchange transfusion for priapism in sickle cell disease. The Journal of Pediatrics. 120(6). 882–885. 72 indexed citations

18.

Reilly, Anne F., et al.. (1992). Hypereosinophilia. Medical and Pediatric Oncology. 20(3). 232–239. 1 indexed citations

19.

Meister, Lynn, et al.. (1991). Leto‐meningeal melanosis. Medical and Pediatric Oncology. 19(1). 42–47. 5 indexed citations

20.

Rackoff, Wayne, Richard A. Rubin, & H. Shelton Earp. (1984). Phosphorylation of the hepatic EGF receptor with cAMP-dependent protein kinase. Molecular and Cellular Endocrinology. 34(2). 113–119. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact